483 Shenzhen Hepalink Pharmaceutical Jan 2013

483 Shenzhen Hepalink Pharmaceutical Jan 2013

Matthew Casale FDA, Gang Wang FDA$119.00 - Available Now

FDA investigators audited the Shenzhen Hepalink Pharmaceutical - Shenzhen, China facility and issued inspectional observations (via FDA 483) on 15 Jan 2013.

Product details

  • Category: Human Drugs
  • Inspection end: 15 Jan 2013
  • Location: Shenzhen, China
  • FEI: 3002808210
Add To Cart